A Multiple Dose Study Of PF-06678552 In Healthy Subjects

Summary

PF-06678552 is a new compound proposed for the treatment of hypercholesteremia. The primary purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of PF-06678552 in healthy subjects.

Conditions

• Healthy

Interventions

DRUG

PF-06678552

PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

DRUG

Placebo

PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

DRUG

PF-06678552

PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

DRUG

Placebo

PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

DRUG

PF-06678552

PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

DRUG

Placebo

PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

DRUG

PF-06678552

PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

DRUG

Placebo

PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

DRUG

PF-06678552

PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.

DRUG

Placebo

PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.

DRUG

PF-06678552

PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.

DRUG

Placebo

PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.

Sponsors & Collaborators

• Pfizer

  lead INDUSTRY

Principal Investigators

• Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2014-03-31

Primary Completion

2014-07-31

Completion

2014-07-31

Countries

• Belgium

Study Locations